Orchestra BioMed recently completed a groundbreaking clinical study on March 6, 2024, to assess the effectiveness of AVIM therapy in...

BTIG analyst Gray Powell is bullish on HashiCorp (HCP) and has increased the price target to $27 from $25. This...

Harvard Bioscience, Inc. is set to unveil its cutting-edge product advancements at the upcoming Society of Toxicology (SOT) conference in...

On March 6, 2024, Bryce Rowe, an analyst at B. Riley Securities, reaffirmed his Sell rating on Stellus Capital Investment...

On March 6, 2024, B. Riley Securities analyst Alex Rygiel reiterated a Neutral rating on L.B. Foster (NASDAQ:FSTR) while increasing...

Jim Suva, an analyst at Citigroup, has decided to maintain a Neutral rating on Cricut (NASDAQ: CRCT) with a revised...

B. Riley Securities analyst Raj Sharma has reiterated his optimistic outlook on American Public Education (NASDAQ:APEI) by maintaining a Buy...

On March 6, 2024, Jefferies analyst Maury Raycroft made a bold move by upgrading Corbus Pharmaceuticals (NASDAQ: CRBP) from a...

Tonix Pharmaceuticals has partnered with EVERSANA to develop a comprehensive launch strategy and commercialization plan for Tonmya, a promising treatment...

Catharine Trebnick, an analyst at Rosenblatt, has reiterated her Buy rating on CrowdStrike Holdings (NASDAQ: CRWD) and raised the price...